Compare LGIH & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | MLTX |
|---|---|---|
| Founded | 2003 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2013 | 2020 |
| Metric | LGIH | MLTX |
|---|---|---|
| Price | $55.73 | $18.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $75.90 | $22.44 |
| AVG Volume (30 Days) | 322.7K | ★ 1.1M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.12 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $18.38 | N/A |
| Revenue Next Year | $7.73 | N/A |
| P/E Ratio | $17.78 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.70 | $5.95 |
| 52 Week High | $77.38 | $62.75 |
| Indicator | LGIH | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 61.77 |
| Support Level | $58.78 | $15.27 |
| Resistance Level | $63.66 | $18.90 |
| Average True Range (ATR) | 2.96 | 0.86 |
| MACD | -0.67 | 0.21 |
| Stochastic Oscillator | 33.14 | 72.77 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.